VRTX Stock Summary and Trading Ideas (Vertex Pharmaceuticals | NASDAQ:VRTX)

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Vertex Pharmaceuticals trades on the NASDAQ stock market under the symbol VRTX.

As of April 21, 2026, VRTX stock price declined to $436.59 with 931,533 million shares trading.

VRTX has a beta of 0.36, meaning it tends to be less sensitive to market movements. VRTX has a correlation of 0.02 to the broad based SPY ETF.

VRTX has a market cap of $110.91 billion. This is considered a Large Cap stock.

Last quarter Vertex Pharmaceuticals reported $3 billion in Revenue and $5.03 earnings per share. This beat revenue expectation by $17 million and exceeded earnings estimates by $.18.

In the last 3 years, VRTX traded as high as $519.88 and as low as $316.43.

The top ETF exchange traded funds that VRTX belongs to (by Net Assets): VTI, VOO, QQQ, IVV, SPY.

VRTX has underperformed the market in the last year with a price return of -10.7% while the SPY ETF gained +35.2%. VRTX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -1.2% and +0.5%, respectively, while the SPY returned +4.2% and +6.9%, respectively.

VRTX support price is $431.74 and resistance is $446.62 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VRTX shares will trade within this expected range on the day.